Dyne Therapeutics Inc DYN 深 沪
等待开盘 03-26 09:30:00 美东时间
19.01
+1.160
+6.50%
华盛通- 最 高19.13
- 今 开18.24
- 成交量 141.51万股
- 最 低 18.24
- 昨 收 17.85
- 总市值 31.37亿
- 52周最高 25.00
- 市盈率 静 --
- 换手率 0.86%
- 52周最低 6.36
- 委 比 -66.30%
- 总股本 1.65亿
- 历史最高 47.45
- 量 比 0.67
- 振 幅 4.99%
- 历史最低 4.30
- 每 手 1
- 风险率 4.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $47
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $50 to $47.
03-04 00:45
财报速睇 | Dyne Therapeutics Inc 2025财年Q4营收0.00亿美元，同比增长0.0%；归母净利润亏损1.12亿美元，同比亏损扩大25.0%
华盛资讯3月2日讯，Dyne Therapeutics Inc公布2025财年Q4业绩，公司Q4营收0.00亿美元，同比增长0.0%，归母净利润亏损1.12亿美元，同比亏损扩大25.0%。
03-02 20:47
Dyne Therapeutics Q4 net loss narrows, beats analyst expectations
Dyne Therapeutics Q4 net loss narrows, beats analyst expectations Overview Biotech firm's Q4 net loss narrowed, beating analyst expectations Company maintains cash runway into Q1 2028 Outlook Dyne plans U.S. Accelerated Approval submission for z-rostudirsen in Q2 2026 Company expects potential U.S.
03-02 20:39
Dyne Therapeutics Q4 EPS $(0.76) Beats $(0.79) Estimate
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.79) by 3.18 percent. This is a 13.64 percent increase over losses of $(0.88) per share from
03-02 20:37
财报速睇 | Dyne Therapeutics Inc 2025财年年度营收0.00亿美元，同比增长0.0%；归母净利润亏损4.46亿美元，同比亏损扩大40.6%
华盛资讯3月2日讯，Dyne Therapeutics Inc公布2025财年年度业绩，公司年度营收0.00亿美元，同比增长0.0%，归母净利润亏损4.46亿美元，同比亏损扩大40.6%。
03-02 20:35
Dyne Q4 net loss USD 112.0 million on R&D expenses USD 95.4 million for FY 2025 R&D expenses USD 398.3 million
Dyne Q4 net loss USD 112.0 million on R&D expenses USD 95.4 million for FY 2025 R&D expenses USD 398.3 million Dyne Therapeutics reported a Q4 net loss of USD 112.0 million and a FY 2025 net loss of USD 446.2 million. Q4 R&D expenses were USD 95.4 million and Q4 G&A expenses were USD 20.7 million, w
03-02 20:31
快讯 | Dyne Therapeutics Inc：重申预计现金跑道将延续至2028年第一季度
Dyne Therapeutics Inc: Reaffirming Expected Cash Runway Into Q1 2028
03-02 20:31
Sarepta CEO To Jump Ship After 'Tumultuous' Year
Sarepta stock drops after a wider loss, Elevidys sales fall 33%, and CEO retirement plans add fresh uncertainty for investors.
02-26 18:52
